GUCY2D p.Asp412=
c.1236C>T · rs61749678 · VCV98539
ClinGen expert panel — Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP
Likely Benign for GUCY2D-related recessive retinopathy. Applied ACMG criteria (verbatim):
BP7 BP4
Curation rationale (ClinGen, verbatim)
NM_000180.4(GUCY2D):c.1236C>T (p.Asp412=) is a synonymous variant in exon 4 of 20. This variant is present in gnomAD v4.1.0 at a total allele frequency of 0.001028 with 1659 alleles / 1,613,498 total alleles, which is higher than the ClinGen LCA/eoRD VCEP PM2_Supporting threshold of <0.0004 and fails to meet this criterion. This variant has a Grpmax allele frequency of 0.001233, with 1519 alleles / 1180008 total alleles in the European (non-Finnish) population, which is lower than the ClinGen LCA/eoRD VCEP BS1 threshold of >0.0016 and fails to meet this criterion as well. The computational predictor REVEL has no data as this is a synonymous variant. The splicing impact predictor SpliceAI gives a delta score of 0, which is below the ClinGen LCA/eoRD VCEP recommended threshold of <0.1 and does not predict an impact on splicing (BP4, BP7). In summary, this variant meets the criteria to be classified as Likely Benign for GUCY2D-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: BP4, BP7. (VCEP specifications version 1.0.0; date of approval 01/22/2025).
ClinGen Evidence Repository → · reported verbatim, not re-tallied by Sugi Variant.
Computational evidence
| Protein change | ||
| Missense predictors do not apply to this variant type; conservation carries the signal. | ||
| Splicing | ||
| SpliceAI | <0.2 | no splice effect predicted · four deltas, not one · how we know |
|---|---|---|
| Constraint at this position | ||
| Conservation | phyloP -0.11 | GERP -1, phastCons 0.001 |
| Overall | ||
| CADD | 3.037 | PHRED · no single calibrated threshold — expert panels disagree |
Population frequency
| Ancestry group | Frequency | 1 in |
|---|---|---|
| European (non-Finnish)grpmax | 0.129% | 777 |
| Admixed American | 0.0966% | 1,035 |
| Finnishnot grpmax-eligible | 0.0599% | 1,670 |
| Remaining individualsnot grpmax-eligible | 0.0448% | 2,231 |
| Middle Eastern | 0.0334% | 2,998 |
| African / African-American | 0.0147% | 6,824 |
| Ashkenazi Jewishnot grpmax-eligible | 0.00338% | 29,600 |
| South Asian | 0.0022% | 45,536 |
Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.
Variant & gene context
- Gene
- GUCY2D
- Protein
- p.Asp412=
- Coding
- c.1236C>T
- MANE Select
- NM_000180
- dbSNP
- rs61749678
- Type
- single nucleotide variant
- Location
- chr17:8006572 (GRCh38)
- Gene constraint
- LOEUF 0.911 · pLI <0.01 (gnomAD)
- Structure
- AlphaFold pLDDT 82.37
Similar variants
- GUCY2D p.Asp412Asn Uncertain significance ★ ⚠ same residue
- GUCY2D c.1956+1G>A Pathogenic ★★★ same condition
- GUCY2D c.3224+1G>C Pathogenic ★★★ same condition
- GUCY2D c.3224+3G>T Likely pathogenic ★★★ same condition
- GUCY2D c.722-1G>T Pathogenic ★★★ same condition
- GUCY2D p.Ala946Thr Likely pathogenic ★★★ same condition
- GUCY2D p.Arg1091Ter Pathogenic ★★★ same condition
- GUCY2D p.Arg313Cys Likely pathogenic ★★★ ⚠ same condition
Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →
Cite Sugi Variant
Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/gucy2d-p-asp412 (accessed [today's date]).
Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown